PFEPfizerSigning up patients
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Multiple Myeloma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,060 (planned)
- Started
- Nov 10, 2022
- Main results expected
- Oct 18, 2030
- Fully finished
- Oct 3, 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1 Dose Limiting Toxicity
Measured over: From the first dose of elranatamab/first full dose in combination with EDR until 28 days (+/- visit window) from the first administration of elranatamab with daratumumab and lenalidomide
Part 2: Progression free survival per IMWG
Measured over: From randomization up to 97 months.
Part 2: Minimal Residual Disease negative CR rate
Measured over: At 12 months after randomization
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05623020 · record last updated 2026-10-27 · checked 2026-11-09 15:47 UTC